The Danish daily, Politiken, recently published an opinion piece by Søren Ziebe, professor, head of the fertility clinic at Rigshospitalet and part of the ReproUnion collaboration, and Ole Sohn, chairman of the board at Cryos ” titled “The children we
Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.
MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.
If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.
“Danish life science is heading for a new golden age”! This is one of the statements put forward in today´s article in Danish daily, Berlingske, highlighting MVA-member, Bioinnovation Institute, and their role as incubator for promising life science companies. A
The annual “Greater Copenhagen Life Science Yearbook” is now awailable online. Apart from the editorial “JOIN FORCES – We are strongest together” by MVA chairman of the Board and Chief Business Officer of IO Biotech, Søren Bregenholt (a must read,
MVA-members and life science decision-makers should all read the recently published and translated article “Venture funds see golden opportunities in Oresunds’s life science hub“(Medwatch subscription needed). A number of prominent experts are interviewed about the potential for venture capital in
The chairman of Medicon Valley Alliance, Søren Bregenholt´s quarterly business column in Copenhagen Post “The Valley of Life: Britain is still key!” has just been published. Read the relatively optimistic analysis of the brexit situation and it´s likely consequences for
In an interview with LIFe-time.se, Medicon Valley Alliance CEO, Petter Hartman, is commenting on the new proposals for strengthening life science in Region Skåne. The region needs to be even better at attracting clinical trials, but what else is needed?
An estimated 700,000 people die each year worldwide from bacterial infections. New antibiotics, rapid diagnostics, vaccines and other products are urgently needed to treat bacteria that are increasingly resistant to existing antibiotics. This is the challenge adressed by the Combating Antibiotic Resistant
“Ascelia Pharma is in a very exciting phase, especially with our main product candidate Mangoral, which is approaching clinical Phase III development and market launch. Meanwhile, we are continuing the development of our second product candidate Oncoral, which completed Phase
Medicon Valley Alliance´s Chairman of the Board since 2015, Søren Bregenholt, has recently been appointed Chief Business Officer at IO Biotech. Leading Danish life science media, Medwatch, interviewed “Novo Nordisk-veteran”, Søren Bregenholt, about his new position and about going from